Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.

Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.

BMC Cancer. 2019 Jun 10;19(1):558. doi: 10.1186/s12885-019-5701-6.

2.

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.

Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX.

Front Pharmacol. 2017 Oct 18;8:730. doi: 10.3389/fphar.2017.00730. eCollection 2017.

3.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V.

Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10. Review.

PMID:
28499515
4.

Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.

Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, Lv TF, Song Y; written on behalf of the AME Academic Lung Cancer Cooperation Group.

Transl Lung Cancer Res. 2017 Dec;6(Suppl 1):S8-S20. doi: 10.21037/tlcr.2017.12.10.

5.

Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.

Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS.

Cancer. 2018 Jan 15;124(2):271-277. doi: 10.1002/cncr.31043. Epub 2017 Sep 28.

6.

Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.

Luo W, Wang Z, Tian P, Li W.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1851-1859. doi: 10.1007/s00432-018-2707-4. Epub 2018 Jul 17. Review.

PMID:
30019319
7.

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.

Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.

Lancet Haematol. 2019 Jan;6(1):e48-e57. doi: 10.1016/S2352-3026(18)30175-3. Epub 2018 Dec 4.

PMID:
30528137
8.

Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.

Nishijima TF, Shachar SS, Nyrop KA, Muss HB.

Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8. Review.

9.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK.

Cancer Immunol Res. 2017 Apr;5(4):312-318. doi: 10.1158/2326-6066.CIR-16-0237. Epub 2017 Feb 28. Erratum in: Cancer Immunol Res. 2018 Apr;6(4):498-499.

10.

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.

Weber JS, Postow M, Lao CD, Schadendorf D.

Oncologist. 2016 Oct;21(10):1230-1240. Epub 2016 Jul 8. Review.

11.

Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.

Sun X, Roudi R, Chen S, Fan B, Li HJ, Zhou M, Li X, Li B.

Medicine (Baltimore). 2017 Nov;96(44):e8407. doi: 10.1097/MD.0000000000008407.

12.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0393. [Epub ahead of print]

PMID:
31021376
13.

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V.

Clin Lung Cancer. 2018 May;19(3):e335-e348. doi: 10.1016/j.cllc.2018.01.002. Epub 2018 Jan 10.

PMID:
29433902
14.

Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.

Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, Suzuki K, Shimizu H, Domeki Y, Terayama K, Nakamura A, Yamanda S, Kimura Y, Honda Y.

JAMA Oncol. 2018 Dec 27. doi: 10.1001/jamaoncol.2018.5860. [Epub ahead of print]

PMID:
30589930
15.

Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.

Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS.

JAMA Oncol. 2016 Dec 1;2(12):1607-1616. doi: 10.1001/jamaoncol.2016.2453. Review.

PMID:
27540850
16.

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T.

BMC Med. 2015 Sep 4;13:211. doi: 10.1186/s12916-015-0455-8. Review.

17.

Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis.

Zhang S, Liang F, Zhu J, Chen Q.

Mol Cancer Ther. 2017 Aug;16(8):1588-1595. doi: 10.1158/1535-7163.MCT-17-0155. Epub 2017 Apr 26.

18.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol. 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022. [Epub ahead of print]

PMID:
31169866
19.

Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?

Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS.

Oncologist. 2019 Apr 29. pii: theoncologist.2019-0094. doi: 10.1634/theoncologist.2019-0094. [Epub ahead of print]

PMID:
31036771
20.

Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.

Judd J, Zibelman M, Handorf E, O'Neill J, Ramamurthy C, Bentota S, Doyle J, Uzzo RG, Bauman J, Borghaei H, Plimack ER, Mehra R, Geynisman DM.

Oncologist. 2017 Oct;22(10):1232-1237. doi: 10.1634/theoncologist.2017-0133. Epub 2017 Jun 26.

Supplemental Content

Support Center